mutations presented the fact that, as spelled out below, CLL therapy is based around the presence or absence of those mutations. The current consensus is, other than clonal mutations, subclonal mutations with a variant allelic frequency ranging from five to ten% (and thus under the threshold of detection by standard molecular techniques) is also re